A detailed history of Childress Capital Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Childress Capital Advisors, LLC holds 5,469 shares of GILD stock, worth $513,812. This represents 0.13% of its overall portfolio holdings.

Number of Shares
5,469
Previous 5,761 5.07%
Holding current value
$513,812
Previous $395,000 15.95%
% of portfolio
0.13%
Previous 0.11%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$66.59 - $83.99 $19,444 - $24,525
-292 Reduced 5.07%
5,469 $458,000
Q2 2024

Aug 05, 2024

BUY
$63.15 - $72.88 $95,167 - $109,830
1,507 Added 35.43%
5,761 $395,000
Q1 2024

Apr 24, 2024

SELL
$71.58 - $87.29 $61,916 - $75,505
-865 Reduced 16.9%
4,254 $311,000
Q4 2023

Feb 16, 2024

BUY
$73.27 - $83.09 $78,911 - $89,487
1,077 Added 26.65%
5,119 $414,000
Q3 2023

Nov 06, 2023

BUY
$73.94 - $80.67 $298,865 - $326,068
4,042 New
4,042 $302,000
Q4 2022

Feb 03, 2023

SELL
$62.32 - $89.47 $53,345 - $76,586
-856 Reduced 14.24%
5,155 $442,000
Q3 2022

Nov 03, 2022

BUY
$59.54 - $68.01 $115,507 - $131,939
1,940 Added 47.65%
6,011 $375,000
Q2 2022

Aug 15, 2022

BUY
$57.72 - $65.01 $14,949 - $16,837
259 Added 6.79%
4,071 $252,000
Q1 2022

May 10, 2022

SELL
$57.92 - $72.58 $63,074 - $79,039
-1,089 Reduced 22.22%
3,812 $226,000
Q4 2021

Jan 26, 2022

SELL
$64.88 - $73.64 $89,729 - $101,844
-1,383 Reduced 22.01%
4,901 $356,000
Q3 2021

Nov 15, 2021

BUY
$67.69 - $73.03 $199,211 - $214,927
2,943 Added 88.09%
6,284 $438,000
Q2 2021

Jul 28, 2021

SELL
$63.47 - $69.35 $164,006 - $179,200
-2,584 Reduced 43.61%
3,341 $230,000
Q1 2021

May 21, 2021

BUY
$60.0 - $68.46 $100,080 - $114,191
1,668 Added 39.18%
5,925 $382,000
Q4 2020

Mar 09, 2021

BUY
$56.65 - $64.55 $241,159 - $274,789
4,257 New
4,257 $248,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Childress Capital Advisors, LLC Portfolio

Follow Childress Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Childress Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Childress Capital Advisors, LLC with notifications on news.